A recent 13G filing with the SEC revealed that Peter Kolchinsky‘s RA Capital Management has acquired more shares of Vitae Pharmaceuticals Inc (NASDAQ:VTAE), as it currently holds 2.12 million common shares of the company, which account for 7.3% of its outstanding stock. According to its 13F filing for the reporting period of June 30, the fund held 1.58 million shares.
Vitae Pharmaceuticals is a biotechnology company engaged in discovering and producing small molecule drugs to treat various diseases. Year-to-date, the company’s stock is down by 51.49%. Recently, Vitae Pharmaceuticals disclosed a loss per share of $0.36 and a net loss of $10.41 million for the second quarter of 2016, compared to a loss per share of $0.45 and a net loss of $9.76 million for the same quarter of 2015. Earlier this month, JMP Securities downgraded its rating on the stock to ‘Market Perform’ from ‘Outperform’, while Wedbush reiterated its ‘Outperform’ rating and has a price target of $23 on it.
Vitae Pharmaceuticals Inc (NASDAQ:VTAE) was in the portfolios of 18 of the hedge funds in our database on March 31, with those investors owning a hefty 55.90% of the company’s stock, making it one of the stocks the investors in our database are the most overweight on. Phill Gross and Robert Atchinson’s Adage Capital Management owned 3.4 million shares of Vitae on June 30.
Follow Vitae Pharmaceuticals Inc (NASDAQ:VTAE)
Follow Vitae Pharmaceuticals Inc (NASDAQ:VTAE)
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| RA Capital Management | 0 | 2,119,036 | 0 | 2,119,036 | 2,119,036 | 7.3% |
| Peter Kolchinsky | 0 | 2,119,036 | 0 | 2,119,036 | 2,119,036 | 7.3% |
| RA Capital Healthcare Fund | 0 | 1,718,343 | 0 | 1,718,343 | 1,718,343 | 6.0% |
Follow Peter Kolchinsky's RA Capital Management
Page 1 of 7 – SEC Filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of
1934
(Amendment No. __)*
Vitae Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
92847N103
(CUSIP Number)
August 5, 2016
(Date of Event Which Requires Filing of
this Statement)
Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:
| ¨ | Rule 13d-1(b) | |
| x | Rule 13d-1(c) | |
| ¨ | Rule 13d-1(d) |
*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).
